Showing 4801-4810 of 5771 results for "".
- First Patient Dosed in Study of Moderna’s mRNA Vaccine Against COVID-19https://modernod.com/news/first-patient-dosed-in-study-of-modernas-mrna-vaccine-against-covid-19/2477403/Moderna announced that the first subject has been dosed in a phase 1 study of its experimental mRNA vaccine mRNA-1273 against SARS-CoV-2. The phase 1 trial, which is being conducted by the US National Institutes of Health (NIH) at Kaiser Permanente Washington Health Research Institute in Seattle,
- Regeneron’s Novel COVID-19 Antibody Program Has Potential to Enter Human Clinical Studies by Early Summerhttps://modernod.com/news/regenerons-novel-covid-19-antibody-program-has-potential-to-enter-human-clinical-studies-by-early-summer/2477404/Regeneron Pharmaceuticals announced the latest progress in its efforts to discover and develop a novel multi-antibody cocktail that can be administered as prophylaxis before exposure to the SARS-CoV-2 virus or as treatment for those already infected. Regeneron scientists have now isolated
- Ribomic Enters License Agreement with AJU Pharma for RBM-007 in AMDhttps://modernod.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-amd/2477400/Ribomic announced that it has signed a license agreement with Korean pharmaceutical company AJU Pharm Co. for RBM-007 for the indication of the exudative age-related macular degeneration (AMD) in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Mala
- Roche Begins Shipments of First 400,000 COVID-19 Tests to Laboratories Across UShttps://modernod.com/news/roche-begins-shipments-of-first-400000-covid-19-tests-to-laboratories-across-us/2477397/Roche announced that it has begun shipping the first allotment of its cobas SARS-CoV-2 Test for COVID-19 (coronavirus) to a network of hospital and reference laboratories across the U.S. to enable automated, high-volume patient testing. Shipping of the initial 400,000 test kits began
- Alirocumab May Cause Scleritis With Uveal Effusionhttps://modernod.com/news/alirocumab-may-cause-scleritis-with-uveal-effusion/2477386/The LDL-cholesterol-lowering agent alirocumab may cause scleritis with uveal effusion, according to the authors of a case report in Annals of Internal Medicine, as reported by Reuters. “Monoclonal antibody therapy is a relati
- Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officerhttps://modernod.com/news/clearside-biomedical-appoints-dr-george-lasezkay-as-president-and-chief-executive-officer/2477375/Clearside Biomedical announced that George Lasezkay, Pharm.D., JD, has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective March 1, 2020. “Clearside has made meaningful pro
- Everads Therapy Enters Into Option Agreement to License Suprachoroidal Delivery System for Retinal Diseasehttps://modernod.com/news/everads-therapy-enters-into-option-agreement-to-license-suprachoroidal-delivery-system-for-retinal-disease/2477376/Everads Therapy announced that it has signed an option agreement with a large global pharmaceutical company, which will support the potential of its technology to overcome certain risks and side effects associated with current retinal disease treatment options, according to a company news release
- Reichert Technologies Signs Exclusive Deal for CATS Reusable Tonometer Prismshttps://modernod.com/news/reichert-technologies-signs-exclusive-deal-for-cats-reusable-tonometer-prisms/2477372/Reichert Technologies has announced its exclusive partnership with CATS Tonometer to distribute the CATS Reusable Tonometer Prism in the United States. The patented CATS Tonometer Prism is superior in IOP accuracy to traditional Goldmann prism, according to a company news release. “For dec
- Nicox Updates on Zerviate Progress in China and Expands the Countries of its Agreement with Ocumension Therapeuticshttps://modernod.com/news/nicox-updates-on-zerviate-progress-in-china-and-expands-the-countries-of-its-agreement-with-ocumension-therapeutics/2477370/Nicox SA announced that it has amended its March 2019 license agreement with Ocumension Therapeutics granting Ocumension exclusive rights to develop and commercialize Zerviate (cetirizine ophthalmic solution), 0.24% for the treatment of allergic conjunctivitis in
- Nicox’s Partner Secures Additional Approval of Vyzulta in Taiwanhttps://modernod.com/news/nicoxs-partner-secures-additional-approval-of-vyzulta-in-taiwan/2477363/Nicox announced that its partner, Bausch + Lomb, has received approval for Vyzulta (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan. This additional approval bring